Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study-Reference-Cited by-同舟云学术

Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study

Published:2015-10-31 Issue:12 Volume:32 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Dhanraj K. M.,Dubashi B.,Gollapalli S.,Kayal S.,Cyriac Sunu Lazar

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-015-0697-5.pdf

Reference26 articles.

1. Fact Sheets by Cancer. [cited 2015 Feb 8]. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx .

2. Desai PB. Breast cancer profile in India: experiences at the Tata Memorial Hospital, Bombay. In: Paterson AHG, Lees AW, editors. Fundamental Problems in Breast Cancer. Springer US; 1987 [cited 2015 Feb 8]. p. 273–9. http://link.springer.com/chapter/10.1007/978-1-4613-2049-4_32 .

3. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36.

4. Lena MD, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1978;1(1):53–9.

5. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11(6):574–89.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer;Journal of Clinical Oncology;2024-09-01

2. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506);Breast Cancer Research and Treatment;2023-06-26

3. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter; NCT02001506);2022-09-08

4. Hand–foot syndrome induced by chemotherapy drug;Indian Journal of Pharmacology;2022-05

5. Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma;Tumori Journal;2018-04-11